Cooper-Vemedia, the European OTC (over-the-counter) drug manufacturer and distributor backed by Charterhouse Capital Partners, has acquired a portfolio of 12 pharmaceutical brands from Sanofi for €158m.
The acquisition is part of Cooper-Vemedia’s strategy to build a pan-European business focused on OTC medicines. The deal is the company’s second material bolt-on under Charterhouse’s ownership.
Charterhouse first backed Cooper in 2015, acquiring the company from Caravelle. In 2016 Cooper purchased Vemedia, a Dutch OTC pharmaceutical company backed by IK Investment Partners.
The Sanofi portfolio includes products split across dermatology, well-being and eye care that are predominantly sold in France and Italy, but also exported to other world markets.
Sanofi has divested the brands as part of a strategy to reduce the complexity of its portfolio and focus on its core business segments of pain, allergy, coughs and colds, digestive health and nutrition.
Cooper-Vemedia chief executive Francis Doblin said the brands enjoyed leading market positions and high consumer awareness and would strengthen Cooper-Vemedia’s position in Europe.
Cooper-Vemedia has a presence in six European OTC domestic markets and various export markets worldwide. It employs around 730 staff.